Parabilis Q2 FY26 net loss widens to $52.46 million; revenue rises to $148,000

Reuters2026/08/13 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Parabilis Medicines posted a Q2 net loss of USD 52.46 million, widening from USD 34.81 million a year earlier.
RD costs climbed to USD 39.38 million from USD 30.13 million, driven by zolucatetide development and higher employee-related costs.
GA expenses rose to USD 11.66 million from USD 6.39 million on higher headcount-related costs and public-company spending.
Cash, cash equivalents, marketable securities totaled USD 1.1 billion at June 30; operations expected to be funded into 2030.
Zolucatetide Phase 3 desmoid trial targeted for H1 2027; FDA discussions planned in Q4 2026, with additional data in Q4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Parabilis Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130700PRIMZONEFULLFEED9809226) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Parabilis Q2 FY26 net loss widens to $52.46 million; revenue rises to $148,000

You may also like

Crypto prices